Amaç: Ailevi hiperkolesterolemi (AH), erken ateroskleroza yol açan aşırı yüksek kolesterol düzeyleri ile karakterize genetik bir hastalıktır. Homozigot AH (HoFH) bulunan olgularda çocukluk döneminden itibaren kardiovasküler olaylar gelişebilmektedir. Bu çalışmada Ege Üniversitesi Tıp Fakültesi, Kardiyoloji Anabilim Dalında izlenen erişkin yaştaki HoFH'li hastalarla olan uzun dönem klinik deneyim sunulmuştur. Çalışma planı: Çalışmaya 2000-2013 yılları arasında izlenen HoFH'lı 17 hasta (11 kadın, 6 erkek) alındı. Hastalara ait tüm veriler (klinik özellikler, aile öyküsü, lipit düzeyleri, tedavileri, lipit aferezi, izlemde gelişen kardiyovasküler olaylar, kompli-kasyonlar vb) geriye dönük olarak hasta dosya kayıtlarından elde edildi. Bulgular: Kliniğimize başvuru sırasında yaş ortalaması 31±10 yıl ve ilk tanı yaşı 25±14 idi. Olguların tanı konulduğunda ortalama kolesterol değerleri 625±136 mg/dl idi, tanı sırasında en sık başvuru yakınmaları deri bulguları (%41) ve iskemi ile ilgili yakınmalarıydı. Üç (%18) olgu ise aile öyküsü nedeniyle tarama yapılırken saptandı. Olguların %65'i akraba evliliği çocuğuydu. Ksantom sıklığı %59 olup aort kapak patolojisi %59, karotis plakları %47 ve koroner arter hastalığı %59 olguda saptandı. Tüm olgularda lipit aferezi endikasyonu bulunmasına rağmen tedavinin reddedilmesinden dolayı 10 olguda uygulanabilmişti. Afereze başlama yaşı 27±12 idi (10-42 yaş). Aferez tedavisine uyum %60'tı. Düzenli aferezle deri bulguları kaybolmasına rağmen hastaların hepsinde karotis aterosklerozunda ve aort patolojisinde ilerleme saptandı. Ortalama 43±42 aylık izlemde dört olgu hayatını kaybetti (ortalama yaş 25±5). Sonuç: HoFH'lı hastalara tanı geç konmaktadır. Aferez tedavisine geç başlandığı için ateroskleroz ve aort darlığı ilerlemektedir. Bu hastalıkla ilgili hekim farkındalığı ve halkın bilinçlendirilmesi gerekmektedir.
Familial hypercholesterolemia (FH) is an inherited metabolic disorder secondary to genetically defective or absent low-density lipoprotein (LDL) receptors. [14] As a consequence of excessively high-serum cholesterol levels, cholesterol accumulate in dermis, tendons, and arterial walls leading to severe cardiovascular (CV) events in young age. Cholesterol typically accumulates in the proximal segments of the vessels. Therefore, stenosis in coronary artery ostium, and aortic valves secondary to accumulation of cholesterol deposits are typical features of the disease. FH demonstrates autosomal dominant inheritance. The untreated cholesterol levels typically range between 250-300 mg/dL in heterozygous individuals, and CV events develop in men by 30-50 years of age, and in women by 40-60 years of age. [5] In homozygous individuals serum cholesterol levels are much higher (500-1000 mg/dl), and severe atherosclerotic events begin from the early childhood. [3, 4] Since these patients have defective LDL receptors antilipid drugs are ineffective. If left untreated homozygous patients generally die before the age of 30 years due to accelerated severe atherosclerotic-CV events. [6] Incidence of homozygous FH (HoFH) has been estimated as one patient per one million people, [17] whereas the incidence of heterozygous form of FH (HeFH) in general population has been accepted as 1/500. However, in recent years, data from closed societies revealed that, FH is more frequent than expected (founder effect). [8] [9] [10] [11] [12] [13] The highest FH prevalence was reported from South Africa (prevalence of HeFH, 1in 70). [11] In French Canadians one of every 270 individuals is estimated to have HeFH. [12] In Lebanon, the prevalence of HoFH is much higher (1/10.000).
[13] In Turkey the incidence of HoFH is unknown, however when prevalence of consanguineous marriages was taken into consideration, rates higher than predicted should be anticipated. Experience with homozygous patients in our country has been reported as sporadic cases, and data on long-term prognosis is not available. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Only a few experienced centers have published short-term results of LDLapheresis from their 5-10 pediatric cases. [24] [25] [26] [27] Data concerning long-term outcomes of adult patients are not available.
In this article long-term clinical experience with adult HoFH patients in a university hospital lipid clinic have been presented. At the same time current approach recommended for HoFH has been reviewed.
PATIENTS AND METHOD
This study was conducted by retrospective screening of the medical records of the HoAH patients followed between 2000-2013 in the Lipid clinic of the Department of Cardiology, Ege University Faculty of Medicine. In our lipid clinic which was established in 1996, treatment regimens of the FH patients depend on the lipid profiles, and biochemical parameters evaluated at 3-to-6 month-intervals. Each patient with established diagnosis of FH, undergoes routine screening tests for the detection of atherosclerosis. These screening tests include ECG, echocardiography, carotid, and vertebral artery Doppler ultrasonography (US), ultrasonographic evaluation of renal arteries, and other arteries based on the presence of clinical findings. All of these imaging modalities are performed using standard methods according to the relevant current guidelines. Fundoscopic examination, and exercise stress tests are also components of the routine evaluation of these patients. According to the detected findings, these examinations are repeated at 6-to-12 month intervals. Measurement of thickness of Achilles tendon which is recommended for the follow-up of patients with FH [28] has been routinely performed since 2012. Thickness of Achilles tendon > 9 mm is regarded as xanthoma. [28] In this study, clinical data were obtained from the medical files which included the parameters evaluated during routine follow-up. Age of the patient at the time of diagnosis reason for first admission, detailed family history (including CV disease, hyperlipidemia, xanthoma, consanguineous marriages), presence of CV disease, atherosclerosis in non-coronary arteries, and aortic stenosis (AS) were recorded. Besides, information relevant to all advanced imaging techniques (coronary angiography, tomography, magnetic resonance imaging) performed in case of need was retrieved from patients'medical files. All lipid measurements recorded in patients'files, lipid levels of the patients before and after sessions of apheresis, and complications of apheresis were evaluated Data are presented as percentages for discrete variables and as mean± SD for continuous variables. Diagnosis of FH was based on extremely increased total cholesterol, and LDL-cholesterol levels, associated with history of familial premature coronary artery disease (CAD), and/or the presence of xanthomas at an early age. Standard SimoneBroome Diagnostic criteria which evaluate presence of typical accumulation of lipid deposits on skin and/or tendons (Table 1) . [29] was used for the identification of the heterozygous family members. Indication of apheresis therapy was determined as LDL-cholesterol levels >500 mg/dl (>300 mg/dl or non-HDL-cholesterol > 300 mg/dL) in accordance with relevant guidelines. [30] [31] Serum lipid levels were measured using standardized methods, and automated analyzers. LDL levels were estimated using both Freidewald formula and in case of suspicion via direct method. Carotid USG findings were evaluated using a linear probe ( 4-9 MHz), and narrowing of > 69 %, calcification in a plaque, presence of turbulent flow, and peak systolic flow velocity of > 230 cm/sec were reported as indicators of severe carotid stenosis.
RESULTS
Clinical characteristics of 17 patients (11 women, and 6 men) with HoFH are summarized in Table 2 . Mean age at admission was 31±10 years. Age at the diagnosis was 2514 years and in only 5 cases diagnosis was made during childhood. Complaints at the time of the diagnosis s were dermatologic (n=7; 41 %), and ischemic (n=7; 41 %). Three patients (18%) were diagnosed during screening for family history of FH. Figure 1 shows the exemplary lipid accumulations of some of our patients. First admissions of all patients were to dermatologists and none of them were questioned for their blood cholesterol levels nor recommended for measurement of their serum lipid levels. In other words diagnosis of FH did not come to any of the attending physician's mind.
Moreover, some patients had their xanthelasmas surgically removed, however the surgeons who performed these procedures had not warned their patients about hypercholesterolemia.
In the present study 65 % of patients had consanguineous marriages in their parents. Family history of all cases revealed higher prevalence of early onset CAD. Xanthoma were observed in 10 (59%) patients. Xanthomas were more prominent in patients whose clinical symptoms started in childhood. In all cases, increase in the thickness of Achilles tendon was detected. Thickness of Achilles tendon of 9 patients ranged between 6 mm, and 13.2 mm (mean, 9.4 ± 2.6 mm). Figure 2 shows thickened Achilles tendon. Aortic valve abnormalities including severe AS (n=2), moderate AS (n=4), and mild AS (n=4), were detected in 10 (59%) patients. And one patient had aneurismatic dilation of ascending aorta. In both cases with severe AS, a second narrowing was detected in the supravalvular region (by echocardiography, magnetic resonance imaging, and angiography). Mean carotid intima-media thickness was 1.85±0.83 mm (range, 0.9 mm-3.1 mm). Carotid arterial plaques were apparent in 8 (47%) patients, while severe stenosis was detected in 3 patients. Figure 3 demonstrates the carotid USG of our 2 cases. CAD was detected in 10 (69 %) patients. Detailed history of CAD of the study population is summarized in Table 3 .
Lipid values of the patients are shown in Table 4 . All of these cases had Type II-a dyslipidemia. At the time of diagnosis mean total cholesterol and LDLcholesterol levels were 625±136 (447-836) mg/dl and 509±121 (359-747) mg/dl, respectively.
All cases received maxim doses of a statin (atorvastatin 80 mg/day or rosuvastatin 40 mg/day) and ezetimibe (10 mg/day).
Apheresis therapy
All patients had definite indications for apheresis therapy. Three cases had had previously undergone apheresis therapy (Cases 2, 3, and 4). However two of them had discontinued their therapy because of problems of transportation and getting tired of therapy (Cases 2, and 3). Only one patient was undergoing regular apheresis therapy for 8 years (Case 4). Initiation of LDL apheresis was recommended to 14 patients in our center. However, one died from CV disease while waiting for the reimbursement process (Case 15). Apheresis could not be initiated in one patient as she was not under the cover of social security (Case 16). Later on, this patient was lost to follow-up. One patient initially accepted the treatment, but she withdrew her informed consent before the first session of the apheresis therapy (Case 17).
Four patients refused apheresis and preferred only drug therapy (Cases 11, 12, 13, and 14). Later on these patients gave informed consent for a multi-center randomized clinical trial with mipomersen therapy. The remaining 7 patients underwent regular LDLapheresis treatment. Besides, apheresis therapy was reinitiated in two patients who had had previous history of short term apheresis (Cases 2 and 3). On a total 9 patients, apheresis therapy was initiated.
One patient couldn't tolerate the therapy after the first session (Case 9), and he couldn't be convinced despite intensive efforts. After the 5th session, another patient (Case 8) expressed that she wouldn't tolerate the sessions because of her complaints similar to those reported by Case 9, and she also stated that she couldn't attend the sessions regularly because of her small children needed her care at home. One patient (Case 10) had to discontinue her therapy at the end of the first year because she had a new job far away from the medical center, however later on she gave informed consent for participation in a multi-center clinical trial with mipomersen.
The most frequently encountered adverse events due to apheresis were hypotension and syncope during the sessions.
Anemia was observed in all patients under apheresis therapy. Three patients received transfusion, and others replacement therapy. One patient experienced catheter infection twice. All patients except one were psychologically intolerant to apheresis as a chronic, time consuming and invasive treatment. Psychiatric consultation revealed that all these patients had major depression. Doppler US examinations of all cases who regularly attended apheresis therapy for more than one year revealed the progression of carotid plaques (Cases 2, 3, 4, 5, 6, 7, and 10). On the other hand, all cutaneous lipid deposits vanished or markedly regressed in all patients who received apheresis therapy at least 2 years (Figure 4) . During follow-up evaluation of 10 patients who underwent apheresis, 3 patients (Cases 1,2, and 3) died, 4 patients (Cases 2,8,9, and 10) discontinued their therapy, and currently 4 patients are still receiving regular apheresis (Cases 4, 5, 6, and 7). Compliance rate to apheresis therapy was 60 percent. One of our regular attenders (Case 4) had been bored with longlasting apheresis therapy since her early childhood and also became depressive as her school were interrupted. Coronary CT angiogram of this patient who had had a coronary artery bypass surgery at the age of 10 revealed the occlusion of one of her saphenous grafts. The second patient (Case 5) who continued to LDL apheresis had undergone coronary artery bypass surgery at the age of 19, and he is still receiving treatment in our center for 2 years. This patient is experiencing difficulties in transportation problem as he is living far very away from our center. One of two female patients who are still undergoing apheresis therapy sessions (Case 6) had had coronary bypass surgery twice in her young age, and she was still struggling with problems of anemia and hypotension. The other patient (Case 7) is experiencing problems of drainage from her fistula during sessions of apheresis.
Cardiovascular events during follow-up
During a mean follow-up period of 48±42 months (2-144 months), two patients were lost to follow-up, and 4 patients were died. One of the deceased (Case 15) had had admitted for the first time to our clinic with acute myocardial infarction, and coronary angiogram revealed severe osteal lesions. She died while waiting for the first session of her apheresis therapy. Other three deceased patients were also in the apheresis therapy group. One of them (Case 1) underwent surgery for persistent coronary ischemia and AS, but she was died during surgery. The second patient (Case 2) underwent regular apheresis therapy for 3.5 years. However, then after he declined apheresis therapy, and died because of advanced heart failure. Case 3, underwent 4.5 years of regular apheresis therapy in our center. However, she died of heart failure a few months after valve surgery. Mean age of the deceased patients was 25±5 (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) years. During follow-up period other cases had anginal complaints without any severe CV events.
In order to describe the inherent characteristics of this peculiar disease in a case base more detailed information about the medical history and clinical course of one of our HoFH patients presented:
This was a young female patient (ŞE, Case 3) living in rural area. She was born to a consanguineous marriage. Parents had noted her her xanthomas when she was 5 years old. Although they seek for therapy the attending dermatologist and primary care physicians did not mention of any lipid metabolism disorder. Moreover, her lipid levels were not measured and her family history was not interrogated. Therefore, her family thought that these painless swellings were harmless, and did not seek for further medical information or treatment. Ten years later, when she was 15 years old, with the complaint of severe angina pectoris, she was referred to a university hospital where she underwent coronary artery bypass surgery Since baseline lipid levels were very high, atorvastatin therapy (20 mg/d) was prescribed. As no improvement was observed attending physicians have initiated her to biweekly regular LDL-apheresis therapy. She could maintain her therapy only for 6 months. Afterwards, the family discontinued her therapy because of financial problems and turned back to rural life. During the next 7 years, she was followed up by a primary care physician with atorvastatin 80 mg daily. In 2008, at the age of 22 years she was referred to our lipid clinic with the severe angina complaints. We added ezetimibe (10 mg/d) to her statin therapy, and weekly LDL-apheresis therapy was initiated. Her examination evealed the presence of AS (hypoplasic aorta with a mean gradient of 54/28 mmHg), and moderate pulmonary stenosis. Her coronary bypass grafts were patent on angiographic imaging. However, la severe aneurysmatic dilation on the anastomotic site between saphenous vein, and circumflex artery was detected ( Figure 5 ). She was consulted to department of vascular surgery, and her hypoplasic aorta was not thought to be suitable for reoperation. She continued biweekly regular LDLapheresis therapy between years 2008 and 2012 in our hospital. During this period, although she was asymptomatic, her AS progressed. As seen in Figure  4 her xanthomas were significantly regressed after two years of regular apheresis therapy. However, she had persistent depressive complaints and psychiatry department initiated treatment with the diagnosis of major depression.
In 2012, as our center experienced problems in purchasing apheresis materials, she preferred to receive apheresis therapy in another center. In that center, she had undergone surgery for AS, but she died a short-time after surgery at an age of 27 years because of progressive heart failure.
DISCUSSION
Familial hypercholesterolemia is characterized by very high levels of plasma cholesterol and earlyonset atherosclerosis. [1] [2] [3] [4] LDL-receptor is a glycoprotein which binds to apolipoprotein B (ApoB)-100 on the surface of LDL particles on hepatocytes, and through this pathway it forms, and internalizes LDL-ligand receptor complex. [32] Numerous (>1700) LDL-receptor mutations have been defined which lead to development of FH. [1, 2, 9] Because of these various types of mutations, plasma cholesterol levels of the patients with FH demonstrate variations depending on the LDL receptor activity. [7, 33] Accordingly, patients with < 2% LDL-receptor activity (receptor negative) tend to have very high levels of cholesterol (usually 800-1000 mg/dl), and clinical picture manifests itself with lipid depositions at early childhood. These "receptor negative," patients do not respond to statins in general and have a poorer clinical outcome. Patients with residual LDLreceptor activity between 2 and 25 %, are defined as "receptor-defective" In this group, clinical picture becomes manifest at 20 or even 30 years of age dependent on the type of the mutation and residual receptor activity. These patients might respond somewhat better to statins. In our homozygous FH population, the first five patients showed relatively more aggravated onset of manifestations of the disease's clinical picture in early childhood, while the rest had their clinical finding to develop in mid-thirties. This variationof clinical picture is related to the underlying genetic mutations on LDL-receptor. Besides LDL-receptor mutations, Apo-B [34, 35] and pro-protein convertase subtilisin/kexin type 9 (PCSK-9) gene [35] mutations can lead to the development of FH. Clinical phenotype originating from all these mutations is variable. For instance, Apo-B mutations exert milder effects among these three mutations. We didn't perform DNAsequence analysis. Diagnosis of HoFH was made based on clinical manifestations in some and known mutations in other patients. Lack of genetic confirmation in every patient should not be considered as diagnostic limitation. Indeed although a genetic disease, definite diagnosis of FH can be made based on its clinical manifestations. [3, 4] Typical characteristic of HoHF is accumulation of cholesterol in tissues predominantly within dermis. These depositions could be in the form of corneal arcus, xanthalesma on eyelids, and xanthomas on skin and/or tendons ( Figure 1 ). In HoFH, lipid deposits can begin to accumulate on skin in very early childhood which is frequently a prodromal finding of the disease. Therefore, as is seen in our patients usually admit priorly to dermatologists or ophthalmologists. Corneal arcus appearing before the age of 50 years, which is seen in 30 % of the case is an important symptom of FH. [3, 4, 28] Xanthomas are especially more prominent on extensor tendons, elbows, Achilles tendon, and hands. Our 10 cases had xanthomas which emerged, and became increasingly widespread during childhood, while xanthomas were not observed in other cases. However, even in cases with genetically confirmed FH, xanthomas may not be present in 20-30 % of the cases. [36] In cases without xanthomas, thickening of Achilles tendon (> 9 mm) has been accepted as xanthomas. [28] Thickness of Achilles tendon was increased in all our patients.
The course of atherosclerosis accelerated in HoFH as they are exposed to extremely high levels of cholesterol since birth. Lipids tend to accumulate in especially proximal segments of blood vessels. Depositions in aortic root result in development of valvular and supravalvular AS.
Among our patient population, in cases whose clinical presentation became apparent before the age of 20 years, AS and severe osteal CAD were detected. Type of the genetic mutation depending on the amount of residual receptor activity affects the extent of atherosclerosis, and the age of its onset. The important finding we observed in our patients with AS is that despite regular LDL-apheresis therapy echocardiographic and clinical improvement were not achieved in aortic stenosis, on the contrary AS progressed. This condition might be explained by late initiation of apheresis therapy. In fact initiation of apheresis is recommended at a very early age (< 6-7 years) for the prevention of AS in homozygous patients. [28, 30, 37] Unfortunately apheresis was initiated in all of our patients after the age of 10 years.
In all patients carotid-intima thickness increased markedly, and calcific plaques were detected. In cases who underwent LDL-apheresis, progresion in carotid lesions were also seen during follow-up. It has been reported that progression or de novo development of CV diseases in 25 % of the patients under regular lipid apheresis. [38] This is observed despite 45-66 % decrease in cholesterol levels relative to baseline values with apheresis. Essentially, apheresis is the most important treatment modality for patients with HoFH. It has been shown that with effective regular LDL apheresis, xanthomas regress (Figure 4) , CV events and inflammatory markers decrease, and endothelial functions improve [39, 40] Notwithstanding all these favorable effects of apheresis, progression of atherosclerotic process can be explained by the short-lived decreases in lipid levels after apheresis. Indeed, target LDL-cholesterol levels in patients receiving apheresis therapy have not been conclusively defined. Relevant guidelines recommend achievement of at least > 50 % decrease in LDL-cholesterol levels per session of apheresis therapy. [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] In our patients generally 50-55 % decrease in LDL-cholesterol levels per session has been achieved. For example, it means that a baseline LDL-cholesterol level of 400 mg/dl will be decreased to 150-200 mg/dl after completion of one apheresis session. However, this level is ensured immediately after the apheresis procedure, and in the following days it rapidly rises back to its baseline values because of unchanged rapidity of Apo-B synthesis. [42] Another remarkable finding of our study, higher rates of refusal and lower compliance of apheresis therapy. Because of invasive and time-consuming nature of the procedure, the patients get tired of the sessions and become noncompliant to therapy. Initiation of apheresis therapy during childhood and adolescence is an important reason for treatment noncompliance. Interruptions in family, school, and professional life adversely contribute to noncompliance to treatment. Because of chronicity of the disease and peculiar characteristics of the apheresis therapy depressive mood develops nearly in all patients which worsens noncompliance to treatment. Besides purchasing necessary materials for apheresis procedures by tender can be delayed, and patients are compelled to live without apheresis therapy. All of these factors can adversely affect the expected benefits from the apheresis therapy.
As is seen, although lipid apheresis is a lifesaving procedure in HoFH, in real life compliance to this hard-to-tolerate treatment is challenging, and it is frequently interrupted. Indeed, new treatment modalities which will be more easily applicable and also ensure longer, and effective decrease in blood lipid levels has been investigated. Novel agents targeting Apo-B levels are promising. three new classes of agent have been introduced into the clinical use from the developmental phases. These innovative agents include PCSK-9 inhibitors which prevent degradation of LDL receptors, anti-sense oligonucleotides which inhibits the synthesis of Apo-B (mipomersen), and microsomal triglyceride transfer protein inhibitor lomit apide which inhibits the transfer of Apo-B to very low-density lipoproteins and chylomicrons. [43] Use of mipomersen, and lomitapide in HoFH was approved by FDA in 2012.
In our study, mortality rate was 26.6 percent (4/15, 2 patients who lost to follow-up were excluded from the analysis). The causes of mortality were surgery for aortic stenosis in two, heart failure due to severe aortic stenosis in one, and acute coronary syndrome in the last patient. However common underlying factors of all these deaths are delayed diagnosis, treatment, and misguidance of the physicians. In fact the most important finding of our case series is that the diagnosis delayed in HoFH. Despite emergence of xanthomas during early childhood combined with family history of premature atherosclerosis, diagnosis was always delayed. It is obvious that awareness of primary care physicians about FH is insufficient. Family screening is important in avoiding delayed diagnosis. [3, 4] However only our three cases were diagnosed as FH during family screening. Family screening allows detection of these patients during childhood, and offers them a chance of early diagnosis. Since cases with FH are exposed to higher cholesterol levels from their early childhood, they carry critically higher risks when compared with dyslipidemic cases with similar blood lipid levels, but without any genetic etiology. With early treatment, survival in both homozygous and heterozygous FH patients markedly prolong. In countries like UK, Holland, and Lebanon, with cascade screening all the first-, and second-degree relatives of a patient diagnosed as FH are screened for lipid levels. [44] In this method genetic tests can be used in case of need. In Holland, with nationwide 'cascade' screening, the number of patients with FH under treatment rocketed from 39% to 93 percent. [45] This is a very important achievement. Indeed in countries having a genetic map for FH, only 15 % of the cases of FH can be diagnosed. [3, 4] FH data related to our country usually come from homozygous case reports presented by one or two centers of apheresis which generally do not contain follow-up information. In only 36 (20 homozygous and 16 heterozygous) cases genetic LDL-receptor sequence analyses have been performed so far, without any follow-up data. [46] Our study is the first to document the long-term clinical course of adult patients with HoFH. With its retrospective design, the results have reflected real-life clinical approach to the disease. On the other hand as reflects the experiences of a lipid clinic of a university hospital, it is more comprehensive, and more consciously conducted than standard approaches.
In conclusion, HoFH is a genetic disease which progresses with accumulation of cholesterol in all over body, and on vessels in the early years of life, and also it is associated with higher mortality secondary to cardiovascular events. Even though a genetic disease it can be clinically diagnosed. And if effective continuous LDL decrease could be achieved survival prolongs significantly. As FH patients are exposed to increased levels of cholesterol since birth early diagnosis is the key point in the success of the management of patients with HoFH. In order to commence early diagnosis and early treatment, awareness of the physicians should be increased. Particularly raising the awareness among primary care physicians regarding high cholesterol levels in children and adolescents would be a substantial step. Public awareness is also an important step. Parents should realize that FH is common disease with high mortality, and that the harms of high cholesterol levels begin in childhood. In order to achieve all these goals, National policy for the diagnosis and treatment of FH should be developed.
